MX377232B
Methods of treatment using selective bcl-2 inhibitors
Abstract
This invention pertains to methods of treating systemic lupus erythematosus, lupus nephritis or Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl 2 anti apoptotic proteins. Specifically, the current invention is directed to treatment with compounds that selectively inhibit the activity of Bcl-2 proteins, with a lesser affinity for inhibiting the activity of other BCL-2 family proteins, including Bcl- x<sub>L</sub>.
Term
6.7 yearsleft in the term
Expires 23 May 2033.
- Priority
- Filed
- Granted
- Today
- Expires
2 priority claims, no other members on record
Priority claims2
| Document | Office | Kind | Date |
|---|---|---|---|
| 41668910 | United States of America | P | |
| 2011061769 | United States of America | W |
Numbers
- Publication
- 377232
- Application
- 2017000835
Titles2
- Spanish
- METODOS DE TRATAMIENTO PARA UTILIZAR INHIBIDORES SELECTIVOS DE BCL-2.
- English
- METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS
Classification
- CPC, 10
- A61K31/496
- A61K31/5377
- A61K45/06
- A61P1/00
- A61P13/12
- A61P27/02
- A61P37/00
- A61P37/02
- A61P37/06
- A61P43/00
- IPC, 2
- A61K31 496
- A61P37 00